Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation

Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancers being non-small cell lung carcinomas. Treatment for this condition is sometimes individualized. With developments in modern treatment and phase III clinical tria...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2021-07, Vol.14 (2), p.1085-1091
Main Authors: Nguyen, Thai Hoa Thi, Pham, Xuan Dung, Dao, Khanh Linh, Vo, Thanh Toan
Format: Article
Language:English
Subjects:
Abdomen
Case Report
Case reports
ceritinib
Chemotherapy
Clinical trials
Drug dosages
Edema
Epidermal growth factor
Lung cancer
Lymphatic system
Magnetic resonance imaging
Medical imaging
Medical prognosis
Metastasis
Mutation
non-small cell lung cancer
osimertinib
Pain
Patients
Pleural effusion
Targeted cancer therapy
Tomography
Tumors
tyrosine kinase inhibitors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancers being non-small cell lung carcinomas. Treatment for this condition is sometimes individualized. With developments in modern treatment and phase III clinical trial results, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and ALK-TKI have proven thier superior effectivity in comparison with the standard platinum-based doublet and are commonly approved as first-line indications in previously untreated advanced non-small cell lung cancer (NSCLC) patients with EGFR or ALK mutations. In the majority of cases, the presence of the ALK rearrangement mutation does not overlap with other mutations in NSCLC. Here, we report a patient with concomitant ALK rearrangement and EGFR mutation treated with a combination of TKIs: osimertinib and ceritinib.
ISSN:1662-6575
1662-6575
DOI:10.1159/000516404